What You Should Know
- The Acquisition: RadNet, a massive U.S. outpatient imaging provider, is acquiring Paris-based radiology AI company Gleamer for up to €230M (($269.05M) in an all-cash transaction. Gleamer will be integrated into RadNet’s digital health subsidiary, DeepHealth.
- The Market Position: The combination of DeepHealth and Gleamer creates the largest provider of clinical radiology AI solutions worldwide, covering MRI, CT, X-ray, Mammography, and Ultrasound modalities.
- The Financial Profile: Gleamer brings a highly lucrative SaaS business model to the table, boasting an ARR compound annual growth rate of over 90% (2022-2025) and tracking toward approximately $30 million ARR in 2026.
- The Operational ROI: Gleamer specializes in automating routine imaging, particularly X-rays. Because X-rays account for nearly 25% of RadNet’s massive imaging volume, deploying Gleamer internally is expected to drive immediate, measurable cost efficiencies and productivity gains across RadNet’s own clinics by Q3 2026.
Mastering the “Routine” X-Ray
While much of the early hype around medical AI focused on detecting obscure, rare diseases, the actual economic engine of an imaging center is routine work. Plain film X-rays account for nearly 25% of RadNet’s total imaging volume.
Gleamer has built a massive footprint—over 700 customer contracts across 44 countries—by mastering this exact niche. The company’s cloud-first AI solutions automate the triaging of musculoskeletal, breast, lung, and neurologic abnormalities.
Crucially, Gleamer excels at automated draft reporting. Instead of a radiologist staring at a blank screen to dictate a standard X-ray result, the AI pre-populates a highly accurate draft report. The radiologist shifts from being a data-entry clerk to a final reviewer, drastically increasing the volume of exams they can safely read in a single shift.
“By building on our combined strengths, we are redefining how imaging is delivered, at scale, with intelligence and automation,” noted Kees Wesdorp, President and CEO of DeepHealth.
The Ultimate Testing Ground
Pure-play software startups often struggle to prove real-world ROI because they lack a captive clinical environment to deploy their code. RadNet, however, operates hundreds of physical imaging centers. By deploying Gleamer’s automated reporting and triage capabilities across its own network, RadNet expects to see measurable productivity gains and operational cost efficiencies by the third quarter of 2026.
Financially, Gleamer is a powerhouse acquisition. The €230M ($269.05M) valuation is backed by a SaaS ARR (Annual Recurring Revenue) compound annual growth rate exceeding 90% from 2022 through 2025. The company is on track to hit approximately $30 million ARR in 2026, armed with four FDA-cleared and six CE-marked devices supporting over 25 clinical indications.
